The National Pancreas Foundation (NPF), a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, has announced that it will build the first-ever national patient registry devoted to all pancreatic diseases, including pancreatic cancer and pancreatitis.
The National Pancreas Foundation (NPF), a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, has announced that it will build the first-ever national patient registry devoted to all pancreatic diseases, including pancreatic cancer and pancreatitis.
“We are very excited to announce the National Pancreas Foundation’s move forward with the only national patient registry for patients suffering from pancreatic cancer, pancreatitis, and other pancreatic diseases,” said Joseph Titlebaum, chair of the National Pancreas Foundation. “Developing the registry will enable greater collaboration amongst researchers and our foundation, increase the quality of patient care and improve patient outcomes for pancreatic disease patients.”
The registry will bring together data from patients and cutting-edge researchers, all working to improve care and develop new and better therapies for individuals suffering from pancreatic disease.
“The NPF registry will be an incredible tool that captures both patient- and physician-entered data,” stated Douglas Pleskow, MD, codirector, GI Endoscopy at Beth Israel Deaconess Medical Center. “Nothing else like this exists, and it will be of great benefit for patients and physicians.”
“The NPF registry will be a true leadership initiative as it leverages a unique cutting edge technology that will allow us and our institutional partners to analyze, visualize, and query the data in a way that will be extremely valuable to the patient community we serve,” said Jane Holt, NPF cofounder.
Addition of Concomitant TTFields Induces OS Benefit in Unresectable Pancreatic Cancer
December 4th 2024The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its primary end point of overall survival in unresectable, locally advanced pancreatic adenocarcinoma.